Moderna, Merck Report Positive Results From Cancer-Vaccine Study
By Nicholas G. Miller
Moderna and Merck's cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.
The companies on Tuesday said the vaccine, in combination with Merck's immunotherapy Keytruda, reduced the risk of recurrence or death by 49% compared with Keytruda alone.
"We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA's potential in cancer care," said Kyle Holen, a senior vice president at Moderna.
The companies had previously released promising three-year data from the study, and on Tuesday they said the treatment "continued to demonstrate sustained and clinically meaningful improvement" in reducing the risk of death and relapse.
The companies currently have eight Phase 2 and Phase 3 clinical trials across multiple tumor types, including melanoma, non-small-cell lung cancer, bladder cancer and renal cell carcinoma.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
Corrections & Amplifications
This was corrected at 7:15 a.m. ET because the original version incorrectly said the cancer vaccine reduced the risk of relapse of death for melanoma patients.
(END) Dow Jones Newswires
January 20, 2026 06:45 ET (11:45 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States